Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Moulis

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Therapie|March 28, 2018
Off-label and unlicensed drug use in children populationFlorence Moulis, Geneviève Durrieu, Maryse Lapeyre-Mestre
European Journal of Clinical Pharmacology|November 1, 2016
Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's diseaseFrançois Montastruc, Florence Moulis, Mélanie Araujo, et al.
Therapie|April 29, 2019
Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance CentreCarole Nicol, Florence Moulis, Emmanuelle Bondon-Guitton, et al.
Developmental Medicine and Child Neurology|September 30, 2016
Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBaseJeanne Montastruc, Philippe Marque, Florence Moulis, et al.
Therapie|July 31, 2017
[Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015]Florence Moulis, Vanessa Rousseau, Delphine Abadie, et al.
Fundamental & Clinical Pharmacology|December 31, 2016
Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase<sup>®</sup> , the WHO pharmacovigilance databaseMélanie Linselle, Agnès Sommet, Emmanuelle Bondon-Guitton, et al.
Journal of the American Medical Directors Association|December 31, 2014
Exposure to atropinic drugs and frailty statusFlorence Moulis, Guillaume Moulis, Laurent Balardy, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 31, 2016
Atropinic (Anticholinergic) Burden in Parkinson's DiseaseSibylle De Germay, Jean-Louis Montastruc, Vanessa Rousseau, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Therapie|March 28, 2018
Off-label and unlicensed drug use in children populationFlorence Moulis, Geneviève Durrieu, Maryse Lapeyre-Mestre
European Journal of Clinical Pharmacology|November 1, 2016
Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's diseaseFrançois Montastruc, Florence Moulis, Mélanie Araujo, et al.
Therapie|April 29, 2019
Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance CentreCarole Nicol, Florence Moulis, Emmanuelle Bondon-Guitton, et al.
Developmental Medicine and Child Neurology|September 30, 2016
Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBaseJeanne Montastruc, Philippe Marque, Florence Moulis, et al.
Therapie|July 31, 2017
[Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015]Florence Moulis, Vanessa Rousseau, Delphine Abadie, et al.
Fundamental & Clinical Pharmacology|December 31, 2016
Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase<sup>®</sup> , the WHO pharmacovigilance databaseMélanie Linselle, Agnès Sommet, Emmanuelle Bondon-Guitton, et al.
Journal of the American Medical Directors Association|December 31, 2014
Exposure to atropinic drugs and frailty statusFlorence Moulis, Guillaume Moulis, Laurent Balardy, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 31, 2016
Atropinic (Anticholinergic) Burden in Parkinson's DiseaseSibylle De Germay, Jean-Louis Montastruc, Vanessa Rousseau, et al.
Pageof 1